// App-Quantinova.ai

PB2114 : Long-Term Use of Tinzaparin for the Treatment of Cancer-Associated Thrombosis: A Subgroup Analysis of the Prospective Observational TROPIQUE Study

Researchers

Presenter

  • C. Frere

Principal Investigators

  • P. Debourdeau

  • A. Lamblin

  • N. Falvo

  • Y. Benhamou

  • M.-A. Sevestre

  • D. Farge

Medical Centers

  • Assistance Publique, Hopitaux de Paris, Hopital Tenon, Paris, France

  • Sorbonne Universites, Paris, France

  • Institut Sainte Catherine, Avignon, France

  • Leo-Pharma, Voisins le Bretonneux, France

  • CHU de Dijon, Dijon, France

  • CHU Rouen, Rouen, France

  • CHU Amiens, Amiens, France

  • University Paris-Sud, Paris, France

  • Montreal University, Montreal, QC, Canada

Locations

  • France

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Pulmonary/Respiratory Diseases

  • Oncology (ONC)

  • Nephrology

  • Cardiovascular (CVS)

  • Blood/haematological Diseases

Disease

  • Renal insufficiency

  • Venous thrombosis

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • Tinzaparin

  • Heparin

Outcome

  • N/A

Study Design

  • Observational

  • Multicenteric

  • Prospective

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved